|
Balance Sheet Cash Flow Statement 750 Lexington Ave., 20th Fl. New York, NY 10022 NY Tel. 212-531-5965 Fax 212-531-5961 |
Type: Public
On the web:
http://www.keryx.com
Employees:
17
Employee growth: (66.0%)
Drugs are a life-or-death business for Keryx Biopharmaceuticals. The company specializes in developing treatments for life-threatening ailments, such as cancer and kidney disease. Its lead candidate is Zerenex, a compound that may reduce high phosphate levels in patients with end-stage renal disease. The company is also developing KRX-0401 (also known as perifosine) to fight renal cell carcinoma and other cancers. Keryx suffered a major blow in 2008 when its previous lead candidate Sulonex failed in a pivotal clinical trial; the drug had been intended to treat diabetic nephropathy, a diabetes-related kidney disease.
Key numbers for fiscal year ending December, 2008:
Sales: $1.3M
One year growth: 22.3%
Net income: ($52.9)M
Officers:
Interim Chairman: Michael P. Tarnok
CEO and Director: Ron Bentsur
VP Finance, Treasurer, and Corporate Secretary: James F. Oliviero
Competitors:
Baxter International
CuraGen
Shire
